Literature DB >> 20431427

Primary treatment of incomplete Kawasaki disease with infliximab and methylprednisolone in a patient with a contraindication to intravenous immune globulin.

Debbie-Ann Shirley1, Ina Stephens.   

Abstract

Incomplete Kawasaki disease was diagnosed in a 3-year-old boy. Because intravenous immune globulin infusion was not tolerated, he was treated with infliximab and methylprednisolone. Coronary aneurysms were not visualized on initial or follow-up echocardiograms. To our knowledge, this is the first report to document the use of infliximab and methylprednisolone as first line therapy for Kawasaki disease.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20431427     DOI: 10.1097/INF.0b013e3181e05564

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  8 in total

1.  [Kawasaki disease in children and adolescents].

Authors:  U Neudorf
Journal:  Z Rheumatol       Date:  2011-12       Impact factor: 1.372

2.  Partial response to anakinra in life-threatening Henoch-Schönlein purpura: case report.

Authors:  Erynn M Boyer; Martin Turman; Kathleen M O'Neil
Journal:  Pediatr Rheumatol Online J       Date:  2011-08-11       Impact factor: 3.054

Review 3.  [Childhood vasculitis].

Authors:  J B Kümmerle-Deschner; J Thomas; S M Benseler
Journal:  Z Rheumatol       Date:  2015-12       Impact factor: 1.372

4.  Should infliximab be used as an adjuvant to IVIG in the treatment of children with Kawasaki disease who are at high risk for resistance to conventional therapy?

Authors:  Shelby Davies; Gabrielle Gold-von Simson
Journal:  Pediatr Cardiol       Date:  2013-06-15       Impact factor: 1.655

5.  Mizoribine provides effective treatment of sequential histological change of arteritis and reduction of inflammatory cytokines and chemokines in an animal model of Kawasaki disease.

Authors:  Kei Takahashi; Toshiaki Oharaseki; Tomokazu Nagao; Yuki Yokouchi; Hitomi Yamada; Noriko Nagi-Miura; Naohito Ohno; Tsutomu Saji; Tomio Okazaki; Kazuo Suzuki
Journal:  Pediatr Rheumatol Online J       Date:  2011-09-29       Impact factor: 3.054

Review 6.  Kawasaki disease: guidelines of Italian Society of Pediatrics, part II - treatment of resistant forms and cardiovascular complications, follow-up, lifestyle and prevention of cardiovascular risks.

Authors:  Alessandra Marchesi; Isabella Tarissi de Jacobis; Donato Rigante; Alessandro Rimini; Walter Malorni; Giovanni Corsello; Grazia Bossi; Sabrina Buonuomo; Fabio Cardinale; Elisabetta Cortis; Fabrizio De Benedetti; Andrea De Zorzi; Marzia Duse; Domenico Del Principe; Rosa Maria Dellepiane; Livio D'Isanto; Maya El Hachem; Susanna Esposito; Fernanda Falcini; Ugo Giordano; Maria Cristina Maggio; Savina Mannarino; Gianluigi Marseglia; Silvana Martino; Giulia Marucci; Rossella Massaro; Christian Pescosolido; Donatella Pietraforte; Maria Cristina Pietrogrande; Patrizia Salice; Aurelio Secinaro; Elisabetta Straface; Alberto Villani
Journal:  Ital J Pediatr       Date:  2018-08-30       Impact factor: 2.638

7.  Changes in 11β-Hydroxysteroid Dehydrogenase and Glucocorticoid Receptor Expression in Kawasaki Disease.

Authors:  Juanli Wang; Nan Zhou; Shouzhen Wu; Xiaoyan Zhang; Decheng Su
Journal:  Korean Circ J       Date:  2017-05-25       Impact factor: 3.243

8.  Intravenous Immunoglobulin Gamma (IVIG) versus IVIG Plus Infliximab in Young Children with Kawasaki Disease.

Authors:  Chun-Ling Han; Suo-Lin Zhao
Journal:  Med Sci Monit       Date:  2018-10-11
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.